Heart Rate Changes Following the Administration of Sugammadex
NCT ID: NCT03294018
Last Updated: 2019-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
276 participants
OBSERVATIONAL
2017-09-06
2019-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heart Rate Response to Regadenoson and Sudden Cardiac Death
NCT01842035
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
NCT05659264
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
NCT05594342
A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin
NCT06625307
Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine
NCT03367026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bradycardia during sugammadex administration
Recording any heart rate changes during planned administration of sugammadex.
Recording heart rate changes
Recording heart rate changes during planned sugammadex administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recording heart rate changes
Recording heart rate changes during planned sugammadex administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anesthetic plan includes NMB reversal with sugammadex
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Joseph D. Tobias
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph D. Tobias
Chairman, Professor of Anesthesiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nationwide Children's Hospital
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB17-00540
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.